Management of NonMuscle Invasive Bladder Cancer: Practical Solutions for Common Problems Webcast (2024)

CME Available: https://auau.auanet.org/node/41097

At the conclusion of this activity, participants will be able to:
1. Implement current practice guidelines and explain methods and resources to improve TURBT skills.
2. Identify the best intravesical agent and duration of therapy for low, intermediate and highrisk NMIBC and what to do during a BCG shortage.
3. Identify methods to treat significant toxicities from various intravesical therapies.
4. Define highrisk scenarios that necessitate cystectomy and options for BCGunresponsive disease.
5. Identify the scientific rationale for investigating immune oncology agents for BCGunresponsive disease and become familiar with current clinical trial designs.

ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from:
Merck & Co., Inc.